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A B S T R A C T
Before and after kidney transplantations, in vitro tests that measure the level of reactivity between donor and recipient
lymphocytes are performed for better organ selection and as indicator of possible organ rejection. In these tests, donor’s
and recipient’s lymphocytes are stimulated for proliferation, which intensity is measured and accordingly organ recipi-
ent reactivity towards graft is determined. Lymph node, spleen and peripheral blood lymphocytes are used for those pur-
poses. For better interpretation of these in vitro tests it should be important to determine mitogenic ability of lymphocytes
of different origin and to choose the most adequate cells. To compare mitogenic ability of deceased donor lymph node,
spleen and peripheral blood lymphocytes one-way mixed lymphocyte culture (MLC) was used. As stimulators irradiated
lymphocytes from spleen, lymph node and peripheral blood samples of 12 deceased donors were used while as responders
lymphocytes from peripheral blood of healthy individuals, chosen according HLA-DRB1 alleles (stimulators and re-
sponders were HLA-DRB1 identical, semi-identical or different), were used. Spleen lymphocyte activity was the best with
different cells and the weakest with identical cells. Impact of polyclonal mitogens (PHA – phytohemagglutinin, Con A –
concanavalin A and PWM – pokeweed mitogen) on lymphocyte proliferation was tested on lymphocytes from spleen and
lymph node of deceased donors. Results abtained in culture in vitro showed that spleen cells had exerted the best mito-
genic potential and PHA had the greatest impact upon lymphocyte proliferation. This investigation is of importance for
establishing the best model to reflect in vivo situation in transplanted patient.
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Introduction
Kidney transplantation has become a fairly common
and effective modality for the treatment of end-stage re-
nal failure. The transplant may be derived from living re-
lated or unrelated donors or a recently deceased individ-
ual (deceased). All allograft recipients are at risk of graft
rejection because the recipient’s immune system recog-
nizes the graft as foreign and seeks to destroy it1–7. The
success rate of kidney transplantation depends on the de-
gree of the compatibility in histocompatibility alleles
(HLA alleles) between donor and recipient3,8–11. The
greater the compatibility the higher probability of sur-
vival and kidney transplant function. Immune reactions
developing after transplantation of genetically non-iden-
tical transplants result in rejection.
In our laboratory, in The Tissue Typing Centre, Uni-
versity Hospital Zagreb, after kidney transplantation, in
vitro tests (MLC – mixed lymphocyte culture, CML – cell
mediated lympholysis) that measure the level of reactiv-
ity between donor and recipient lymphocytes are per-
formed in order to predict and follow the outcome of kid-
ney transplantation. Lymph node, spleen or peripheral
blood lymphocytes are used for those purposes12.
Mitogens, as substances which cause DNA synthesis,
blast transformation and ultimately division of lympho-
cytes are used in CML in vitro tests. For studying and an-
alyzing mechanisms of lymphocyte activation, division,
proliferation and maturation, phytomitogens such as
phytohemagglutinin (PHA), concanavalin A (Con A) or
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pokeweed mitogen (PWM) can be used12. PHA, Con A
and PWM are polyclonal activators that can stimulate
lymphocytes in a nonspecific manner, without involving
antigen-specific receptors, and they cause lymphocyte
transformation into lymphoblasts5,13–18.
For better interpretation of results it is necessary to
choose most adequate cells (lymphocytes) as the best in
vitro model for presenting and monitoring posttrans-
plantation immunological events in vivo. Therefore we
used spleen, lymph node and peripheral blood lympho-
cytes in one-way mixed lymphocyte culture (MLC) for de-
termination and comparison of their mitogenic abili-
ty19–22. As control experiment mitogenic impact of vari-
ous phytomitogens (PHA, Con A and PWM) on spleen,
lymph node and peripheral blood lymphocytes was com-
pared.
Materials and Methods
Lymphocyte samples
In The Tissue Typing Centre spleen, lymph node and
peripheral blood samples from deceased organ donor are
delivered for regular pre- and post-transplant testing.
These samples are used for tissue typing (determination
of HLA alleles) and crossmatch before transplantation
and for numerous tests in post-transplantation monitor-
ing of recipients. We used lymphocytes from spleen,
lymph node and peripheral blood for the one-way MLC
test. Irradiated lymphocytes from spleen, lymph node
and peripheral blood samples of 12 deceased donors were
used as stimulators while as responders, lymphocytes
from peripheral blood of healthy individuals, volunteers
from laboratory personnel were used. Lymphocyte re-
sponders and stimulators were used in three combina-
tions: 1) stimulators and responders were HLA-DRB1
identical, 2) stimulators and responders were HLA-DRB1
semi-identical, 3) stimulators and responders were HLA-
-DRB1 different (Table 1). Impact of polyclonal mitogens
on lymphocyte proliferation was tested on lymphocytes
from spleen, lymph node and peripheral blood from de-
ceased donors.
Lymphocyte separation
Lymphocytes were isolated from the spleen, mesen-
teric lymph nodes and heparinised blood. Fresh hepa-
rinised blood (2 tubes of 8 mL) was mixed with an equal
volume of physiological solution and placed into 50 mL
sterile conical centrifuge tubes. 10 mL of Lymphoprep
(Ficoll-Triosill solution, density 1,077 g/cm3) was slowly
layered underneath the blood/physiological solution mix-
ture by placing the tip of the pipette containing the
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TABLE 1
LYMPHOCYTE STIMULATORS AND RESPONDERS IN MIXED LYMPHOCYTE CULTURE
Stimulators Responders
Sample HLA classes I and II HLA-DRB1 identical HLA-DRB1 semi-identical HLA-DRB1 semi-identical HLA-DRB1 different
K1
A24, 25, B17, 18,
DRB1*07, *15
R1
(*07, *15)
R2
(*03, *07)
R3
(*11, *15)
R4
(*03, *11)
K2
A23, 24, B40, 44,
DRB1*07, *11
R5
(*07, *11)
R2
(*03, *07)
R3
(*11, *15)
R6
(*13, *16)
K3
A2, –, B13, 15,
DRB1*13, *15
R7
(*13, *15)
R3
(*11, *15)
R8
(*07, *13)
R2
(*03, *07)
K4
A2, 3, B7,40,
DRB1*11, *15
R3
(*11, *15)
R1
(*07, *15)
R4
(*03, *11)
R2
(*03, *07)
K5
A1, 24, B8, 44,
DRB1*03, *11
R4
(*03, *11)
R2
(*03, *07)
R9
(*01, *11)
R6
(*13, *16)
K6
A2, 11, B18, 51,
DRB1*01, *11
R9
(*01, *11)
R10
(*01, *12)
R4
(*03, *11)
R6
(*13, *16)
K7
A2, 11, B61, 35,
DRB1*11, *12
–
R10
(*01, *12)
R4
(*03, *11)
R8
(*07, *13)
K8
A24, 11, B27, 35,
DRB1*01, –
–
R9
(*01, *11)
–
R4
(*03, *11)
K9
A1, –, B8, –,
DRB1*03, –
R11
(*03, –)
R2
(*03, *07)
–
R12
(*11, *16)
K10
A2, –, B51, 44,
DRB1*16, –
R13
(*16, –)
R6
(*13, *16)
–
R2
(*03, *07)
K11
A2, –, B51, 27,
DRB1*11, *16
R12
(*11, *16)
R6
(*13, *16)
R4
(*03, *11)
R2
(*03, *07)
K12
A2, 24, B17, 51,
DRB1*03, *14
R14
(*03, *14)
R2
(*03, *07)
R15
(*14, *16)
R6
(*13, *16)
K1-12 – deceased organ donor cells (stimulators), R1-15 – healthy individuals cells (responders)
Lymphoprep at the bottom of the sample tube. Tube was
centrifuged at 2500 rpm at room temperature (18° to
20°C) for 20 minutes. Centrifugation sedimented eryth-
rocytes and polynuclear leukocytes to the bottom of the
tube. With a sterile pipette, mononuclear lymphocyte
layer, which formed above the Lymphoprep, was trans-
ferred to a 15 mL centrifuge tube and centrifuged for 15
minutes at room temperature and 1800 rpm. After re-
moval of the supernatant, cells were resuspended in
physiological solution, centrifuged for 15 minutes at room
temperature and 1800 rpm. Supernatant was removed
again and mononuclear cells were resuspended in RPMI
1640 (Institute of Immunology, Zagreb, Croatia), counted
and viability was determined by trypan blue exclusion.
Spleen and lymph nodes were placed in Petri dishes
and thoroughly syringed with physiological solution. Cell
suspension from Petri dish was carefully layered over 10
mL of Lymphoprep in a sterile 50 mL centrifuge tube to
create a sharp cell suspension-Lymphoprep interface and
centrifuged at 2500 rpm at room temperature for 20 min-
utes. Mononuclear lymphocyte layer was aspirated and
transferred to a 15 mL centrifuge tube and centrifuged
for 15 minutes at room temperature at 1800 rpm. Cells
were washed with physiological solution, resuspended in
RPMI 1640, counted and viability was determined. Cells
were ready for immediate use or cryopreservation for fu-
ture use.
Mixed lymphocyte culture (MLC)
One-way MLCs between lymphocytes isolated from
peripheral blood, lymph node or spleen of 12 deceased
(stimulators) against peripheral blood lymphocytes (PBL)
of 15 healthy individuals chosen according their HLA-
-DRB1 alleles (responders) were performed (Table 1). Ir-
radiated lymphocytes from peripheral blood, lymph node
or spleen of each deceased (stimulators) were cultured
with HLA-DRB1 identical, semi-identical or different
PBL (responders) of healthy individuals.
Lymphocytes responders and stimulators were sus-
pended to 5´105/mL in RPMI 1640 supplemented with
10% heat-inactivated human AB serum (Institute of Im-
munology, Zagreb, Croatia). MLCs were performed in
triplicate in 96-well round-bottom microtiter plates (Co-
star, Cambridge, MA, USA).100 mL of lymphocyte re-
sponders were cultured with an equal amount of irradia-
ted lymphocyte (2000Gy) stimulators. MLCs were incu-
bated for 5 days at 37°C, in 5% CO2/95% air humidified
atmosphere. On the fifth day of culture, 1% methyl
tritiated thymidine (Amersham [6-3H] Thymidine, Aque-
ous solution, GE Healthcare, UK; 0,05 mCi per well) in
RPMI solution was added (50 mL/well) to the cultures. In-
corporation of methyl tritiated thymidine was measured
on the sixth day of culture. Cultures were harvested into
deepwell LumaPlates 96 (PerkinElmer). The filter plates
were counted in b-counter (Hidex Chameleon). Data are
given as the average of triplicate samples.
Mitogens
The content of one bottle freeze dried PHA (PHA
HA16, Murex Diagnostics Ltd, Dartford, England) was
diluted in 5 mL of sterile RPMI, and stored frozen in
aliquots at –20°C until use. Con A (Sigma-Aldrich Inc,
Saint Louis, Missouri, USA) was applied (5 mg) to a 10
mL amber serum vial. PWM (Biochrom KG, Berlin, Ger-
many) was applied (0.1 mL) in a 1.9 mL RPMI (Institute
of Immunology, Zagreb, Croatia).
Stimulation with mitogens
Lymphocytes from spleen, lymph node or PBL of de-
ceased donors were stimulated with different mitogens
(Con A, PHA and PWM). Lymphocytes were suspended
to 1´106/mL in RPMI 1640 supplemented with 10% heat-
-inactivated human AB serum (Institute of Immunology,
Zagreb, Croatia), 20 mL/mL human recombinant IL-2
(Roche Diagnostics GmbH, Roche Molecular Biochemi-
cals, Mannheim, Germany) and 5 mL/mL one of the afore-
mentioned mitogens. In experimental groups, 1–2 mL of
cells was cultured in 24-well microtiter plates (Costar,
Cambridge, MA USA). Cultures were incubated for 3
days at 37°C, in 5% CO2/95% air humidified atmosphere.
After that, 200 mL of each cell culture suspension was
placed in 96-well deepwell LumaPlates 96 (PerkinEl-
mer), 50 mL 1%methyl tritiated thymidine in RPMI solu-
tion was added (50 mL/well) and culture was incubated
for another 18 hours in the same way. Radioactivity was
measured on the next day as described before.
Results
The mitogenic capability of lymph node, spleen or pe-
ripheral blood lymphocytes was tested by MLC. Periph-
eral blood, lymph node and spleen lymphocytes from 12
deceased donors were used as stimulators and peripheral
blood lymphocytes from healthy individuals were used as
responders. There were three combinations of lympho-
cyte responders and stimulators: 1) stimulators and re-
sponders that were HLA-DRB1 identical, 2) stimulators
and responders that were HLA-DRB1 semi-identical, 3)
stimulators and responders that were HLA-DRB1 differ-
ent, except for the autolog control where stimulators and
responders were lymphocytes from the same person.
Lymphocyte stimulators were irradiated and thus only
lymphocyte responders were capable of proliferation.
Proliferation of responders was detected by methyl tri-
tiated thymidine incorporation 18 hours before harvest-
ing. Results were given as mean counts per minute in
triplicate wells (cpm) (Table 2).
Comparison between spleen, lymph node and
peripheral blood lymphocytes as stimulators of
alloimmune reaction
For identical HLA-DRB1 lymphocytes results of MLC
tests have shown that spleen lymphocytes were the best
stimulators in 60% of cases, while in 20% of cases each,
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lymph node and peripheral blood lymphocytes were the
best stimulators (Figure 1).
Results of MLC tests for semi-identical HLA-DRB1
lymphocytes are shown in Figure 2 and Figure 3. In
61,9% samples of spleen lymphocytes, in 28,6% of lymph
node lymphocytes and in 9,5% peripheral blood lympho-
cytes were shown to be the best stimulators.
For HLA-DRB1 different lymphocytes spleen lympho-
cytes were the best stimulators in 50% of cases, lymph
node in 33,3% and peripheral blood lymphocytes in 16,7%
of cases (Figure 4).
Analyzes of all MLC tests imply that spleen lympho-
cytes are the best proliferative promoters for HLA-DRB1
different cells and the weakest proliferative promoters
for HLA-DRB1 identical cells (Figure 5).
Plant mitogen effect on lymphocyte proliferation
In the second part of this study the impact of different
plant mitogens (PHA, Con A or PWM) upon spleen,
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TABLE 2
MIXED LYMPHOCYTE CULTURE TEST RESULTS
Stimulators Stimulators
Sample 1 Sample 2
Responders
(Peripheral blood)
Spleen
Lymph
node
Peripheral
blood
Responders
Spleen
Lymph
node
Peripheral
blood
cpm cpm cpm cpm cpm cpm
Autolog control 335 292 N.C. Autolog control 181 142 144
HLA-DRB1 identical R1 246 164 212 HLA-DRB1 identical R5 240 141 386
HLA-DRB1 semi-identical R2 360 301 204 HLA-DRB1 semi-identical R2 302 3242 667
HLA-DRB1 semi-identical R3 449 258 389 HLA-DRB1 semi-identical R3 289 4746 1319
HLA-DRB1 different R4 903 684 1352 HLA-DRB1 different R6 312 2161 1287
Sample 3 Sample 4
Autolog control 191 149 210 Autolog control N.C. N.C. N.C.
HLA-DRB1 identical R7 146 119 229 HLA-DRB1 identical R3 433 218 372
HLA-DRB1 semi-identical R3 646 1616 584 HLA-DRB1 semi-identical R1 2429 1471 2700
HLA-DRB1 semi-identical R8 394 246 287 HLA-DRB1 semi-identical R4 3064 3053 2616
HLA-DRB1 different R2 2508 2992 752 HLA-DRB1 different R2 7144 9173 3034
Sample 5 Sample 6
Autolog control 260 N.C. 192 Autolog control 385 147 218
HLA-DRB1 identical R4 384 535 414 HLA-DRB1 identical R9 233 113 208
HLA-DRB1 semi-identical R2 1072 2438 2352 HLA-DRB1 semi-identical R10 302 249 204
HLA-DRB1 semi-identical R9 959 2756 2385 HLA-DRB1 semi-identical R4 2620 495 1385
HLA-DRB1 different R6 1931 1441 1258 HLA-DRB1 different R6 1150 4288 4974
Sample 7 Sample 8
Autolog control 223 257 716 Autolog control 2514 3102 N.C.
HLA-DRB1 semi-identical R10 348 135 124 HLA-DRB1 semi-identical R9 470 424 N.C.
HLA-DRB1 semi-identical R4 3756 2508 694 HLA-DRB1 different R4 2042 1843 N.C.
HLA-DRB1 different R8 1885 184 211
Sample 9 Sample 10
Autolog control 370 137 N.C. Autolog control 198 N.C. N.C.
HLA-DRB1 identical R11 202 174 199 HLA-DRB1 identical R13 256 236 N.C.
HLA-DRB1 semi-identical R2 459 149 192 HLA-DRB1 semi-identical R6 352 159 N.C.
HLA-DRB1 different R12 1175 424 851 HLA-DRB1 different R2 3398 2107 N.C.
Sample 11 Sample 12
Autolog control 567 N.C. 288 Autolog control 226 172 N.C.
HLA-DRB1 identical R12 1917 974 379 HLA-DRB1 identical R14 362 158 187
HLA-DRB1 semi-identical R6 3139 1178 738 HLA-DRB1 semi-identical R2 1143 2468 1083
HLA-DRB1 semi-identical R4 3916 1093 934 HLA-DRB1 semi-identical R15 1106 1053 343
HLA-DRB1 different R2 9612 7734 3545 HLA-DRB1 different R6 1005 1085 323
cpm = counts per minute, R1-15 – lymphocyte responders, N.C. – not enough cells for test
lymph node and peripheral blood lymphocyte transfor-
mation was analyzed. After 3 days of treatment with
mitogens (PHA, Con A or PWM), transformation of lym-
phocytes was noted. Typical big blast cells forming clus-
ters at the bottom of wells were present. PHA, Con A and
PWM stimulation of lymphocyte proliferation was mea-
sured by methyl tritiated thymidine uptake. Results were
given as mean counts per minute per culture (cpm) (Ta-
ble 3).
Comparison between PHA, Con A and PWM impact
on spleen lymphocytes from deceased donors showed
that PHA stimulation induced the most significant pro-
liferative response while lymph node lymphocytes also
showed a significant proliferative response when induced
with PHA. By simultaneous culture of spleen and lymph
node lymphocytes with PHA, spleen lymphocytes exerted
a better proliferative response to PHA stimulation.
Discussion and Conclusion
The MLC (mixed lymphocyte culture) used in this
study together with CML (cell-mediated lympholysis)
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Fig. 1. Comparison of alloimmune reactions of spleen, lymph
node and peripheral blood lymphocytes from different deceased
organ donors (samples K1-K12) with HLA-DRB1 identical per-
sons. cpm – counts per minute.
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Fig. 2. Comparison of alloimmune reactions of spleen, lymph node
and peripheral blood lymphocytes from different deceased organ
donors (samples K1-K6) with HLA-DRB1 semi-identical persons
(samples R1-R10). cpm – counts per minute.
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Fig. 3. Comparison of alloimmune reactions of spleen, lymph node
and peripheral blood lymphocytes from different deceased organ
donors (samples K7-K12) with HLA-DRB1 semi-identical persons
(samples R2-R15). cpm – counts per minute.
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Fig. 4. Comparison of alloimmune reactions of spleen, lymph
node and peripheral blood lymphocytes from different deceased
organ donors (samples K1-K12) with HLA-DRB1 different per-
sons. cpm – counts per minute.
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Fig. 5. Comparison of alloimmune reactions of spleen lympho-
cytes from different deceased organ donors (samples K1-K11) with
HLA-DRB1 identical, semi-identical and different persons. cpm
– counts per minute.
TABLE 3
STIMULATING EFFECT MITOGENS ON SPLEEN, LYMPH NODE
AND PERIPHERAL BLOOD LYMPHOCYTES PROLIFERATION
Cells Samples
Phytomitogens
PHA Con A PWM
cpm cpm cpm
Spleen
lymphocytes
K1 193 6 130 114
K4 17 971 10 953 N.C.
K5 10 619 8 554 896
K6 2 161 N.C. N.C.
K8 279 N.C. N.C.
K10 13 011 12 071 4 747
K11 15 039 8 808 5 554
Lymph node
lymphocytes
K1 11 347 N.C. N.C.
K6 227 N.C. N.C.
K7 9 527 N.C. N.C.
K12 15 910 584 6452
Peripheral blood
lymphocytes
K10 313 116 164
PHA – phytohemagglutinin, Con A – concanavalin A, PWM –
pokeweed mitogen, cpm – counts per minute, K1-12 – cell de-
ceased organ donors, N.C. – not enough cells for test
represent traditionally used tests for pretransplantation
evaluation of adequate donor-recipient pairs19,23–25. In
these tests, lymphocytes from donor (stimulators) and
lymphocytes from recipient (responders) are mixed to-
gether in tissue culture. While CML test measures the
cytotoxic T-cell reactivity to mismatched HLA class I an-
tigens of donor, the MLC test measures the degree of pro-
liferation recipient leukocytes to respond to HLA class II
differences expressed by donor leukocytes. Although some
of the common and newly developed cellular, humoral,
genomic and proteomic tests to assess the immune status
of the transplant recipient have been developed19,23,26–30,
the MLC test has been used in the most recent study of
human stem cells to establish allorecognition of human
neural stem cells by peripheral blood lymphocytes30. The-
refore, the MLC and CML tests may be regarded as in vi-
tro versions of in vivo transplantation and have been also
used for transplant monitoring after organ transplanta-
tion20,31–33. Monitoring the immune response to the allo-
graft permits the early identification of patients at risk
for rejection and graft loss, monitoring responses to the
therapy after intervention, and guides the development
of new immunosuppressive therapies26,34,35. Immune mo-
nitoring might aid in differentiating rejection from other
forms of graft dysfunction and drug toxicity.
Most recently, these tests have been used in the post-
transplantation setting to identify patients who are hy-
poresponsive, who display decreased alloresponses to do-
nor and to predict of the optimal immunosuppressive
dose for individual patient36–39 in order to personalize
immunosuppressive therapy for the each patient. Several
studies report that donor antigen-specific hyporespon-
siveness, defined as a significantly lower MLC or CML
between the recipient and donor after transplantation, is
associated with lower incidence of chronic rejection and
improved graft outcome36,40–42.
In our laboratory, before and after kidney transplan-
tation, in vitro tests (MLC and CML/AD CML -cell-medi-
ated lympholysis/antibody depended cell-mediated lym-
pholysis) for better organ (kidney) selection and as indica-
tor of possible organ rejection are routinely performed.
For these tests blood samples of patients and blood sam-
ples, lymph node or spleen samples of donors are used.
Present study using the MLC test has shown that spleen
lymphocytes were in most cases better stimulators then
lymph node and peripheral blood lymphocytes. As ex-
pected, spleen lymphocyte activity was the best with
HLA-DRB1 different cells and the weakest with HLA-
-DRB1 identical cells, HLA-DRB1 being HLA class II an-
tigens with more than 321 known alleles which makes
them the most polymorphic protein-encoding regions of
the human genome43. These results support the clinical
benefit of HLA-DRB1 matching and previous findings
that HLA matching correlates with improved graft (kid-
ney, heart) survival44. There are a numerous studies with
results which confirm that degree of HLA-DR mismatch
in particular, correlates with freedom from early acute
rejection and long-term graft survival45,46. Accordingly,
HLA-matching can clearly reduce the number of targets
for alloantigen-specific antibodies and both direct and in-
direct pathway T effector cell response. HLA-class II
matching might also favour the activity of the natural T
regulatory (Treg) cells restricted by self class II, and the
generation of adoptive T regulatory (Treg) cells that in-
hibit alloreactive B and T cells. Even partial HLA-DRB1
match is better than none. Some papers show how to im-
prove graft (kidney, pancreas-kidney, heart) outcome with
patient (recipient) pretransplant blood transfusion shar-
ing an HLD-DR antigen with blood/organ donor. Both
clinical and in vitro models suggest that these HLA-DR
shared transfusions may lead to down-regulation of the
immune response against allogeneic HLA antigens pre-
sented by transplantated organs. These down-regulation
of alloreactive cells is the result of the induction of
CD4+Treg cells that recognize an allopeptide in the con-
text of a self HLA class II molecule47,48.
Donor-recipient HLA compatibility has been also the
leading predictor of outcome after allogeneic blood or
marrow transplantation (BMT). Increasing degrees of
HLA mismatch at either the antigen or allele level have
been repeatedly associated with worse overall outcomes
in series of myeloablative, related or unrelated donor
BMT for hematologic malignancies. The reported effect
of HLA disparity on relapse risk has been variable. Al-
though some studies have found a lower relapse risk with
increasing degrees of HLA mismatch or specific mis-
matches, suggesting a graft-versus-tumor effect, this has
generally been offset by higher rates of graft-versus-host
disease (GVHD), graft failure, and nonrelapse mortality
(NRM). Thus, although one or more partially-HLA mis-
matched (HLA-haploidentical) first-degree relatives can
be readily identified in most patients who lack a histo-
compatible donor, the toxicity of such transplants has
prevented many centers from pursuing this approach.
Recent study suggests that with nonmyeloablative, par-
tially-HLA mismatched, T-cell replete BMT that com-
bines high-dose cyclophosphamide and standard post-
grafting immunosuppression, greater HLA disparity does
not appear to worsen overall outcomes49 and new ap-
proach of allogeneic stem-cell transplantation (allo-SCT)
as salvage therapy for patients with diffuse large B-cell
non-Hodgkin’s lymphoma relapsing after an autologous
stem-cell transplantation (ASCT) is a promising thera-
peutic modality for patients with a long remission after
ASCT and with sensitive disease at allo-SCT50.
In a control experiment of this study, all types of do-
nor cells could proliferate under different mitogens but
in all combinations tested, PHA impact on spleen lym-
phocytes was the best which might be of importance also
for blast transformation necessary for CML, AD/CML.
Our results of comparison of spleen, lymph node and
peripheral blood lymphocytes as stimulators of alloreac-
tivity according to HLA-DRB1 matching showed that
spleen lymphocytes were the most adequate and suitable
in vitro model for immunological events in vivo.
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LIMFOCITI LIMFNOG ^VORA, SLEZENE I PERIFERNE KRVI KAO STIMULATORI
ALOREAKTIVNOSTI
S A @ E T A K
Prije i nakon transplantacije bubrega rade se in vitro testovi kojima se mjeri razina reaktivnosti izme|u limfocita
primatelja i davatelja radi {to boljeg odabira davatelja organa te radi utvr|ivanja mogu}eg odbacivanja organa. U tim
testovima limfociti primatelja i davatelja se poti~u na proliferaciju, intenzitet proliferacije se mjeri te se na temelju toga
odre|uje reaktivnost primatelja organa prema presatku. Pritom se koriste limfociti slezene, limfnog ~vora ili periferne
krvi. Za bolju interpretaciju tih in vitro testova va`no je odrediti mitogenu sposobnost limfocita iz razli~itih izvora
(periferna krv, slezena, limfni ~vor) te izabrati najprikladnije stanice za upotrebu {to boljeg in vitromodela. Kako bismo
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usporedili mitogenu sposobnost limfocita limfnog ~vora, slezene i periferne krvi koristili smo jednosmjerni test mije-
{ane kulture limfocita (MLC). Kao stimulatore smo koristili ozra~ene limfocite iz uzoraka limfnog ~vora, slezene i
periferne krvi 12 mrtvih davatelja, dok su nam responderi bili limfociti periferne krvi zdravih osoba izabranih prema
HLA-DRB1 alelima (tako da su stimulatori i responderi bili HLA-DRB1 identi~ni, poluidenti~ni i razli~iti). Utjecaj
poliklonskih mitogena (PHA – fitohemaglutinin, Con A – konkanavalin, PWM – korovski mitogen) na proliferaciju
limfocita smo testirali na limfocitima slezene i limfnog ~vora mrtvih davatelja. Rezultati dobiveni u kulturi in vitro
pokazali su da stanice slezene imaju najsna`niji mitogeni potencijal. Od svih testiranih poliklonskih mitogena, PHA
poti~e najobilniju proliferaciju. Ovo istra`ivanje je va`no za uspostavu najboljeg in vitro modela koji prikazuje in vivo
situaciju u transplantiranih bolesnika.
M. Puc et al.: Lymphocytes as Stimulators of Alloreactivity, Coll. Antropol. 35 (2011) 2: 369–376
376
